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Abstract
Background: Extra virgin olive oil (EVOO) has shown beneficial effects on the lipid profile and inflammatory parameters in
general population. Our goal is to analyze these changes together with those of intestinal microbiota in human immunodeficiency
virus (HIV)-infected patients over 50 years of age.
Methods: Experimental single arm open study. HIV patients over the age of 50 with undetectable viral load were selected. EVOO
was distributed among the patients so that each one consumed 50g daily for 12 weeks. Lipid profile, C-reactive protein (CRP), and
intestinal microbiota composition were analyzed at the beginning and at the end of the intervention.
Results: Total cholesterol decreased significantly (5mg/dL), and a nonsignificant decrease in low-density lipoprotein cholesterol
(12 mg/dL), triglycerides (21mg/dL), and CRP (1.25 mg/dL) was observed. There was a significant increase in alpha diversity
after the intervention in men and a decrease in proinflammatory genera such as Dethiosulfovibrionaceae was observed. Differences
were also observed in the microbiota of men and women and according to the type of antiretroviral treatment.
Conclusion:Sustained consumption of 50g of EVOO in elderly HIV-infected patients might be associated with an improvement in
lipid profile and alfa diversity of intestinal microbiota.
Abbreviations: ART= antiretroviral treatment, BC= Bray–Curtis, CRP=C-reactive protein, DNA= deoxyribonucleic acid, EVOO
= extra virgin olive oil, FTC = emtricitabine, HIV = human immunodeficiency virus, IBD = inflammatory bowel disease, II = integrase
inhibitor, IQR = interquartile range, LDA = linear discriminant analysis, LDL = low-density lipoprotein, MSM =men who have sex with
men, NNRTI = nonnucleoside reverse transcriptase inhibitors, OTU = operational taxonomic unit, PCR = polymerase chain reaction,
RPV = rilpivirine, TAF = tenofovir alafenamide, VL = viral load.
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1. Introduction
Human immunodeficiency virus (HIV) infection conditions a
chronic inflammatory state that is not completely reversed with
an effective antiretroviral treatment (ART).[1] This inflammatory
state is associated with an increase in the incidence of non-AIDS
events, such as cancer or cardiovascular events, among others.[2–
4] A key point in maintaining this condition is the intestinal
microbiota,[5–7] which is modified by HIV itself, increasing
proinflammatory bacterial species, such as Firmicutes and
Prevotella and decreasing Bacteroides.[8–10] The use of probiotics
has been tested in patients with HIV infection,[11,12] with
decreases in inflammatory markers such as IL-6 or D-dimers, as
well as prebiotics[13] and symbiotics.[14]
Olive oil is a fundamental component of the Mediterranean
diet. Virgin olive oil is obtained by mechanical extraction from
olives. Extra virgin olive oil (EVOO) is extracted from the highest
quality olives, with an acidity of less than 1%. In patients not
infected by HIV, with high vascular risk, daily consumption of
50g of EVOO has been associated with a decrease in mortality
and cardiovascular events (HR 0.69) compared to a low-fat
diet.[15] This reduction was dependent on the dose of polyphenols
received.[16] These beneficial clinical effects seem to be a result of
different mechanisms. A crucial milestone in the formation of
atheromatous plaque is the oxidation of low-density lipoprotein
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(LDL) cholesterol and high-density lipoprotein cholesterol, since
these oxidized particles will deposit their content inmacrophages.
It has been proven how the percentage of oxidized LDL decreases
as the intake of polyphenolic compounds in olive oil increases
along with an increase in high-density lipoprotein cholesterol
levels in a dose-dependent manner.[17] The administration of
olive oil rich in polyphenols has also demonstrated the
improvement of endothelial function[18] and reduction of levels
of inflammatory markers.[19] In addition, nonabsorbable EVOO
polyphenols are metabolized by the gut microbiota through
decarboxylation and demethylation processes, increasing Lacto-
bacillus[20] and Bacteroidaceae.[21] The increase in Lactobacillus,
which codifies a hydroxylase of the bile salts, conditions the
division of bile acids, which prevents their reabsorption and they
are excreted along with cholesterol in the feces. Moreover, the
polyphenols in olive oil have shown to inhibit the growth of
intestinal pathogens such as Escherichia coli[22] or Helicobacter
pylori[23] in vitro. Different studies have also demonstrated the
antiproliferative effect of EVOO in neoplastic cell lines, as well as
showing an antioxidant and antiinflammatory effect.[24,25]
The published experience on the effects of the use of EVOO in
patients with HIV infection is very scarce,[26] suggesting a
positive effect on inflammatory markers such as ultrasensitive C-
reactive protein (CRP), so we aimed to observe the effects of daily
EVOO intake in a group of patients with chronic HIV infection
and long-term ART use, analyzing its effects on the lipid profile,
inflammatory parameters, and intestinal microbiota.
2. Methods
An experimental open study of a single arm was performed at the
Costa del Sol Hospital (Marbella, Spain) during the first semester
of 2018. Patients with chronic HIV infection, on ART for at least
1 year before inclusion in the study or elite controllers, aged
between 50 and 75 years at the time of inclusion in the study were
selected. They needed to have presented undetectable viral load
(VL) for at least 6 months prior to inclusion and a CD4
lymphocyte count in peripheral blood less or equal to 200cells/
mL in the previous 12 months. Previously, a questionnaire on
dietary habits was performed on all patients in the cohort over 50
years old, entering the study those who presented figures of daily
EVOO consumption of less than 10g per day. Exclusion criterion
was the presentation of diarrhea or antibiotics in the 8 weeks
prior to inclusion, consumption of illicit drugs, HBV or HCV
coinfection, any AIDS event in the previous year, daily alcohol
consumption of at least 20g, chronic liver disease, inflammatory
bowel disease (IBD), previous cardiovascular events and cancer
of any type in the previous 5 years (excluding nonmelanoma skin
cancer and anal cancer as long as it was in situ carcinoma), and
use of nonsteroidal antiinflammatory drugs, corticosteroids,
immunosuppressants, or probiotics in the last 12 weeks. After
signing the informed consent, blood samples were taken, fecal
samples were given by patients for microbiota investigation, and
a physical activity questionnaire was completed (International
Physical Activity Questionnaire). The study was approved by the
local Ethics Committee. Once the samples had been collected, the
patients received 750mL bottles of EVOO donated by Bravoliva
Ltd, this EVOO was a mixture of Hojiblanca olive varieties
(80%), chamomile (10%), and picuda (10%) with an acidity of
0.25%. Sufficient bottles were given fortnightly to guarantee a
daily consumption of 50mL. In addition, a weekly call was made
to patients to reinforce adherence to the intervention and to
identify the presence of side effects and to record if diarrhea or
antibiotics use had occurred. The intervention was maintained
for 12 weeks.
At the end of the intervention, glucose levels, CRP, lipid profile,
homeostatic model assessment index, glomerular filtration rate
estimated by the Chronic Kidney Disease-Epidemiology Collab-
oration formula, and N-terminal pro B-type natriuretic peptide
levels were determined. HIV-1 VL along with CD4 and CD8
lymphocytes counts was measured. Results are shown as median
and interquartile range (IQR) for quantitative variables, and as
percentage for qualitative variables. Quantitative values were
compared through nonparametric tests (Mann–Whitney U) and
Chi square for categorical variables.
Fecal samples were collected in plastic sterile containers from
each volunteer and then transferred to 80 °C conservation
conditions until analysis. Fecal samples were homogenized in a
Stomacher-400 blender. Deoxyribonucleic acid (DNA) was
extracted using a QIAamp DNA Stool Mini Kit (QIAGEN,
Barcelona, Spain) as directed by the manufacturer, with the
exception that samples were mixed with the lysis buffer and
incubated at a temperature of 95 °C instead of 70 °C to ensure lysis
of both gram-positive and gram-negative bacteria. Quantification
was conducted with a NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientific, DE). The DNA yield was determined by
measuring absorbance ratios spectrophotometrically, and the
measurement includes A260/280nm for protein contamination
and A260/230nm for salt and phenol contamination.
Microbiome was analyzed using the V3 chemistry in a MySeq
Illumina platform. The extracted DNA was polymerase chain
reaction (PCR) amplified using the primer pairs, with a 16S
Amplicon PCR Forward Primer: 50TCGTCGGCAGCGTC-
AGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG,
and 16S Amplicon PCR Reverse Primer: 50GTCTCGTGG-
GCTCGGAGATGTGTATAAGAGACAGGACTACHVGGG-
TATCTAATCC targeting the V3 and V4 hypervariable regions
of the bacterial 16S rRNAgene. All PCRswere performed in 25m
L reaction volumes containing 12.5mL 2X KAPA HiFi Hotstart
ready mix (KAPA Biosystems, Woburn, MA), 5mL of each
forward and reverse primers (1mM) and 2.5mL of extracted
DNA (10ng) under the following cycling conditions: initial
denaturation at 95 °C for 3minutes, followed by cycles of
denaturation at 95 °C for 30seconds, annealing at 55 °C for 30
seconds, and elongation at 72 °C for 30seconds, with a final
extension at 72 °C for 5minutes. PCR clean-up was performed
using AMPure XP beads (Beckman Coulter, Indianapolis, IN) to
purify the 16S V3 andV4 amplicon from free primers and primer
dimer species. Then the next step was the PCR index, in this step
attaches dual indices and Illumina sequencing adapters using the
NexteraXT IndexKit (Illumina, SanDiego,CA), PCRconditions
were: 95 °C for 3minutes; 8 cycles of 95 °C for 30seconds, 55 °C
for 30seconds, 72 °C for 30seconds; 72 °C for 5minutes, and
hold at 4 °C. The pooled PCR products were purified using
AMPure XP beads (Beckman Coulter, Indianapolis, IN) before
quantification. The resultant ampliconswere sequenced atMiSeq
(Illumina, San Diego, CA), using paired-end (2x300nt) Illumina
MiSeq sequencing system (Illumina).
2.1. Microbiota analyses
We used Usearch (v11, https://drive5.com/usearch/) suite to make
the operational taxonomic unit (OTU) analysis. First, we checked
the quality and metrics of the samples using FastQC. Trimming
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and merging of the reads were done by Usearch command
fasq_mergepairs. The fastq_filter command was used to filter the
merged sequences, only retaining those that had at least 335pb
and a maximum of 1 error (maxee 1.0). We followed the uparse
pipeline from Usearch (http://www.drive5.com/usearch/manual/
uparse_pipeline.html) for the OTU analysis. First of all, we
dereplicated the sequences, identifying unique sequences. Next
we used the clusterotus command to discard single unique reads
(with the option, minsize 2), eliminate the chimeras, and cluster
the OTUs, using the UPARSE algorithm (http://www.drive5.
com/usearch/manual/uparseotu_algo.html). This clusterization
was done at 97% identity. The original input sequences were
mapped onto the OTUs with 97% similarity using the otutab
command. The taxonomy assignation of the OTUs was made
using the SINTAX algorithmwith the command sintax at 99% of
identity, and the GreenGenes database v13.5.
Six different a-diversity indices were estimated: richness/
observed OTU, Chao1 Richness, Abundance-based Coverage
Estimator, Shannon–Wiener index, Equitability, Simpson,
Inverse Simpson, and Dominance for diet, gender, and ART.
Differences in a-diversity were estimated using a paired
Wilcoxon rank test for diet for univariate analysis and Nonlinear
Mixed-Effects Models for multivariate analysis.
For b-diversity analyses, Bray–Curtis (BC), unweighted, and
weighted UniFrac distances (wUniFrac) were calculated with
permutational multivariate analysis of variance (PERMANOVA)
which was performed on the OTU abundance profile of all
samples to assess the effect of diet on b-diversity, 999
permutations were used to obtain the permuted P-value in R.
The relative abundance of each OTU was calculated for each
sample, and the OTUs were combined at phylum, genus, and
species levels. For each sample type, the overall abundance of
each level was calculated by taking the sum of relative
abundances by levels in all subjects. Taxa with a lower
abundance of 1% were joined into the same category.
LefSe analysis (linear discriminant analysis [LDA] effect size)
was used for discovery of diet, gender, and ART-related bacterial
genus and species taxa. The LefSe algorithm uses a nonparamet-
ric factorial Kruskal–Wallis sum rank test, unpaired Wilcoxon
rank-sum test, and LDA to estimate the effect size of each
differentially abundant OTU/taxon. The threshold on the
logarithmic score of LDA analysis was set to 1.0 for diet and
ART and set to 2.0 for gender.
All analyses were adjusted for multiple testing using the
Benjamini and Hochberg procedure (FDR<0.05). Statistical
analyses were performed using R 3.5.1.
3. Results
A total of 20 patients were recruited, of which 18 completed the
intervention. The remaining 2 did not attend the scheduled
appointments. Adherence to the intervention was 95%, there
were no cases of diarrhea or antibiotic consumption during the
study and no interruptions of the intervention.
Median age of the patients was 54.5 years (IQR: 7), 7 (38.9%)
were women and 11 (61.1%) were men.Median number of years
since diagnosis was 9.5 (IQR: 17) and median duration of ART
was 9 years (IQR: 6.5). Regarding the route of infection, 10
(55.6%) reported unprotected heterosexual practices, 4 (22.2%)
were men who have sex with men (MSM), and 4 (22.2%) were
former injecting drug addicts.
Regarding ART, 8 patients were receiving the combination of
tenofovir alafenamide (TAF), emtricitabine (FTC), and rilpivirine
(RPV); 3 received TAF, FTC, and elvitegravir-cobicistat; 3 the
combination of abacavir (ABC), lamivudine (3TC), and
dolutegravir. Three of the remaining 4 cases received a different
ART: dual therapy with darunavir-cobicistat (DRV-cb)+RPV,
TAF, FTC and DRV-cb and ABC+3TC+etravirine. One patient
was an elite controller and did not receive any ART. The CD4
lymphocyte nadir was 263cells/mL (IQR: 277).
A total of 10 patients (55.6%) did not take nonantiretroviral
medication. The rest of the patients took benzodiazepines (3
cases), calcium, vitamin D, and alendronate (3 cases), antagonists
of angiostensin II receptors, proton pump inhibitors, statins, and
tamsulosin (2 cases for each medication). Seven patients (38.9%)
were active smokers, and 5 were ex-smokers (27.8%). Median
BMI was 25kg/m2 (IQR: 4.68). At the time of inclusion in the
study, all patients had VL<50copies/mL, except one who had
VL of 57copies/mL. At the end of the intervention, all patients
had VL<50copies/mL. Main results of the different parameters
studied at baseline and at 12 weeks of the intervention are shown
in Table 1. There were only significant changes in total
cholesterol levels, with a substantial decrease in the levels of
CRP, LDL cholesterol, and triglycerides.
3.1. Analysis of the microbiota
The samples from 18 patients could be analyzed, but in 2 of
them only baseline samples were taken, which makes a total of
32 samples from 16 patients.
When analyzing the alpha diversity indices (Richness,
Shannon–Wiener, Chao1, Abundance-based Coverage Estima-
tor, Equitability, Simpson, Dominance, Inverse Simpson), no
statistically significant differences were observed before and after
the intervention.
However, when adjusting the effect of diet by gender, as can be
seen in Figure 1, statistically significant differences were observed
for men in the Shannon–Wiener index (P= .048) and Equitability
index (P= .036).
Regarding the beta-diversity, no significant differences in
the interindividual composition of the microbiota before and
after the intervention (BC P= .834, wUniFrac P= .997, UniFrac
P=1000) were observed, even when adjusting by gender and
Table 1
Results of the main analytical parameters: median and inter-
quartile range.
Parameter Baseline 12 wk P
CD4 lymphocytes, cells/mL 648 (457) 636 (284) .055
CD4/CD8 0.77 (0.51) 0.73 (0.64) .71
Glucose, mg/dL 95 (11) 96 (8) .75
Glomerular filtration-CKD-EPI, mL/min 88 (16) 85 (19) .39
Triglycerides, mg/dL 123 (56) 102 (58) .13
Total cholesterol, mg/dL 208 (73) 203 (65) .03
LDL cholesterol, mg/dL 136 (39) 127 (42) .13
HDL cholesterol, mg/dL 50 (13) 49 (13) .56
NT-proBNP, ng/L 37 (53) 51 (137) .27
CRP, mg/dL 3 (14) 1.75 (4) .13
HOMA 1.6 (1.5) 1.4 (0.67) .5
CD= cluster of differentiation, CKD-EPI=Chronic Kidney Disease-Epidemiology Collaboration,
CRP=C-reactive protein, HDL=high-density lipoprotein, HOMA=homeostatic model assessment,
LDL= low-density lipoprotein, NT-proBNP=N-terminal pro B-type natriuretic peptide.
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ART of patients (BC P= .994, wUniFrac P= .993, UniFrac
P= .997).
When studying significant gain of genus with the intervention,
an increase in Gardnerella was observed, and a decrease of
Mogibacterium, Dethiosulfovibrionaceae, and Coprococcus
(Fig. 2). As for species, a gain of Bulleidia moorei and a decrease
of the Bacilli species were observed.
Significant differences were observed depending on gender of
the patients, as shown in Figure 3, with an increase of Prevotella,
Bacteroidetes, Bifidobacterium, Erysipelotrichaceae, and Eubac-
terium in males, while in women Eggerthella, Ruminococcus,
Lachnospiraceae, Parabacteroides, and Akkermansia were more
abundant.
Interestingly, significant differences were observed depending
on whether patients were on an integrase inhibitor (II) or a
nonnucleoside reverse transcriptase inhibitors (NNRTI) based
ART. In those who used an II, Bifidobacterium and Actino-
bacterium were more abundant, while those using NNRTI had a
greater abundance of Bacteroidales and Bulleidia (Fig. 4).
Receiving one or the other ART did not influence the effect of
EVOO on microbiota.
4. Discussion
In this study, the use of EVOO in patients of over 50 years of age
with HIV infection showed a significant decrease in total
Figure 1. Alpha diversity indexes for intervention, controlling for gender.
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cholesterol, as well as an increase in the alpha diversity of the
microbiota in males. In addition, the use of EVOO showed a
decrease in proinflammatory genera such as Dethiosulfovibrio-
naceae. Finally, a different profile in the composition of the
microbiota according to the type of ART received was found.
These findings suggest a beneficial effect of sustained consump-
tion of 50g of EVOO in elderly HIV-infected patients.
Previous studies in non-HIV population have shown that
EVOO rich in nonabsorbable polyphenols is associated with
significant decrease in CRP levels.[18] Experience in HIV-infected
patients is limited, although there has also been evidence of a
decrease in CRP levels in patients who used older ART regimens
that are no longer in use.[26]
In addition, the use of EVOO showed an increase in
Gardnerella and a decrease in proinflammatory genera such as
Dethiosulfovibrionaceae. In this study, a significant increase in
alpha diversity was observed in males. The diversity of the
intestinal microbiota is reduced in HIV-infected patients
compared to uninfected individuals,[27–29] as in patients with
IBD,[30] there is a relationship between a greater alpha diversity
and a higher level of CD4 lymphocytes in peripheral blood of
naive patients, as well as with lower levels of markers of
activation of peripheral blood monocytes and bacterial translo-
cation.[31] In this study, it has been found that a simple dietary
intervention can increase alpha diversity in elderly patients with
effective ART. This effect of increased alpha diversity is the same
as the effect observed in patients who initiate ART with a degree
of severe immunosuppression,[32] although the same has not been
demonstrated in patients with better immunological status.[5] In
fact, some studies have associated the use of ART to a reduction
in alpha diversity.[31] In these patients, part of the beneficial effect
on alpha diversity can be explained by the immune reconstitution
after an effective ART; however, this would not be the case of the
patients included in this study, which had a long period of ART
with a very good viroimmunological situation, so we believe that
the effect on alpha diversity can only be attributed to the EVOO
intake. Changes in diet rapidly induce changes in the diversity
and composition of the microbiota,[33] at least in individuals not
infected with HIV. In this study, the intervention was maintained
for 12 weeks, trying to mimic the effect of introducing EVOO
into diet in a sustained manner. Other authors have also reported
a differential effect of diverse types of ART on the modification of
alpha diversity in the intestinal microbiota, increasing in patients
that receive triple therapy based on II or NNRTI.[27] In this study,
EVOO increased alpha diversity in men regardless of ART
received. The effect of EVOO on the microbiota seems to be
mediated by nonabsorbable polyphenols,[34] which reach the
intestinal lumen, being metabolized by the microbiota.[35]
Previous studies in non-HIV hypercholesterolemic patients have
shown an increase in the proportion of Bifidobacterium
associated with the consumption of virgin olive oil enriched in
polyphenols.[36]
On the other hand, Dethiosulfovibrionaceae increases its
frequency in the microbiota of other chronic inflammatory
conditions such as IBD, and can produce compounds that are
toxic to human cells,[37,38] so the effect of EVOOwould be clearly
positive in this case.
Previous studies with probiotics (a mixture of fructo-
oligosaccharides, galacto-oligosaccharides, and glutamine) have
not shown to increase alpha diversity, but have in beta diversity,
thus inducing changes in microbiota structure without inducing
an increase in the diversity of the species.[39] Specifically, an
increase in Bifidobacteriaceae was observed in viremic patients
without ART, without observing any significant change in
patients following ART.
In this study, differences were observed between the composi-
tion of the microbiota in men and women. Although it is known
that the composition of the microbiota may be modified partially
by sexual habits inMSM,[29,40] this should not be the case for this
study, as only 4 of the male participants were MSM. An
enrichment was observed in species such as Prevotella copri was
observed in males, which has already been evidenced in other
studies[5,6,28,39] and also in Erysipelotrichaceae. In the case of the
latter, its in vitro capacity to induce the increase in the production
of tumor necrosis alpha and interleukin-10 of non-HIV
individuals[6] has been shown. Prevotella has been associated
Figure 2. LEfSe analysis of ACOVE dataset by diet.
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with an increase in activated CD4 lymphocytes[8] and in
proatherogenic metabolites.[41] On the other hand, genera linked
to the production of butyrate such as Lachnospira[42] or
Ruminococcus,[43] or linked to the antiinflammatory response,
such asAkkermansia,[44] showed greater abundance in the group
of women.
Significant differences were also observed in the composition of
the microbiota according to the ART received by the patients,
Figure 3. LDA score by gender. LDA= linear discriminant analysis.
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with an increase in Bacteroidales in patients who continued
treatment with NNRTI and an increase in Bifidobacterium and
Actinobacteria in those receiving II. The increase in the
proportion of Bacteroidales has been associated in other studies
to the activation of CD8+T cells[45]; on the contrary, depletion of
Bifidobacterium is one of the changes of the microbiota
associated with aging,[46] its abundance is linked to the
antiinflammatory response.[44] There was no influence of ART
type on alpha or beta diversity, as has already been observed in
individuals who initiate ART with a good immunological
situation.[32] In NNRTI’s case, at least efavirenz has been shown
to inhibit the growth of E coli and Bacillus subtilis,[47] thus
influencing the composition of the intestinal microbiota. In this
study, the NNRTI used was RPV, of which no data on influence
on the composition of microbiota is available so far.
Generally, studies on the microbiota of HIV patients have been
carried out in patients of a younger age,[10,27,29,32,39] but only
elderly patients were recruited in this study, because they are the
ones with the highest incidence of non-AIDS events. The patients
had a CD4 lymphocyte count of more than 600cells/mL, so it
remains to be seen if in patients with a worse immune status,
EVOO would produce the same effects.
This study has several limitations. First, the small sample size
has possibly limited the fact that we have seen significant
differences in the improvement of the lipid profile or the CRP. In
second place, all patients were elderly with ART based on
NNRTI or II along with 2 nucleos(t)ide analogues, so the effect
observed in these patients cannot be extrapolated to other
scenarios such as dual therapy or triple therapy based on protease
inhibitors. Third, this study was a single-arm study, with no
control arm. Fourth, an objective measure of adherence to the
intervention, as the determination of hydroxytyrosol in urine,
was not performed, but a weekly telephone follow-up was made.
In conclusion, the findings of the present study, for the first time
ever, showed that a beneficial effect of the sustained consumption
of EVOO (12 weeks) was associated with a decrease in total
cholesterol and an increase in the alpha-diversity of the
microbiota in males. As these findings suggest a beneficial
effect of the sustained consumption of 50g of EVOO in elderly
HIV-infected patients, we believe that this pilot study merits
confirmation of its conclusions in a study with larger population
and with a longer follow-up.
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